Related Experiment Videos
The epidermal growth factor receptor as a target for therapy in breast carcinoma
1Laboratory of Receptor Biology, Memorial Sloan-Kettering Cancer Center, New York NY 10021.
Abstract:
The epidermal growth factor (EGF) receptor and its ligands have an important regulatory role in breast carcinoma. We have produced a series of monoclonal antibodies (MAbs) directed against the external portion of the EGF receptor. These MAbs prevent the binding of the ligands to the receptor, block ligand-induced activation of the receptor, and can inhibit the growth of breast cancer cells both in tissue culture and in human tumor xenografts in nude mice. We have also shown that anti-EGF receptor antibodies greatly enhance the antitumor effects of chemotherapeutic agents active in breast cancer. Phase I clinical trials with single doses of MAb conducted in patients with tumors over-expressing EGF receptors demonstrated favorable pharmacokinetics, good tumor imaging, and a lack of toxicity. A human:murine chimeric antibody has been produced with comparable affinity and antitumor activity that will enable us to administer repeated doses of MAb either alone or in combination with chemotherapy. Our pre-clinical data support the concept that the EGF receptor may be an optimal target for treatment with receptor blocking antibodies, either alone or in combination with chemotherapy.
Insights
Monoclonal antibodies targeting the epidermal growth factor (EGF) receptor inhibit breast cancer growth and enhance chemotherapy. Clinical trials show safety and efficacy, supporting EGF receptor as a therapeutic target.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Epidermal growth factor (EGF) receptor plays a key role in breast carcinoma.
- EGF receptor signaling drives tumor growth and progression.
Purpose of the Study:
- To develop and evaluate monoclonal antibodies (MAbs) targeting the EGF receptor for breast cancer treatment.
- To assess the efficacy of MAbs alone and in combination with chemotherapy.
Main Methods:
- Production of MAbs against the extracellular domain of the EGF receptor.
- In vitro and in vivo studies using breast cancer cell lines and xenografts.
- Phase I clinical trials in patients with EGF receptor-overexpressing tumors.
Main Results:
- MAbs blocked ligand binding and receptor activation, inhibiting cancer cell growth.
- Anti-EGF receptor antibodies enhanced antitumor effects of chemotherapy.
- Phase I trials showed favorable pharmacokinetics, tumor imaging, and safety.
Conclusions:
- EGF receptor is a viable target for antibody-based therapies in breast cancer.
- MAbs targeting EGF receptor can be used alone or combined with chemotherapy for improved outcomes.